Company intelligence / Profile preview

Eternapure

Ownership: Private
Development stage: Other

Overview

Eternapure markets dietary supplements featuring pharmaceutical-grade chondroitin 4-sulfate delivered via a patented liposomal system, with claims of improved absorption and efficacy for joint health, inflammation, and connective tissue support; no clinical trials referenced, so efficacy is based on consumer reports and biochemical rationale rather than peer-reviewed clinical data[1][2][3][4].

Therapeutic areas: ImmunologyNeurologyRheumatology
Modalities: Small moleculeLipid nanoparticle delivery therapy
Industry: Food & Nutrition

Beyond the preview

Go deeper on Eternapure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eternapure.

Explore the full profile